Biotechnology

Gossamer Bio's recent 200,000-share grant to a new hire is more than a welcome bonus; it's a strategic bet on its blockbuster drug candidate.

A prestigious Yale recognition for board member Dr. Curtis Patton bolsters Tevogen's credibility as it advances its AI and T-cell platforms.

A regulatory filing from Balyasny Asset Management reveals intense investor activity as a bidding war for narcolepsy drugmaker Avadel heats up.

A newly validated 'longevity protein' is fueling a biotech gold rush, but can companies turn breakthrough science into viable medicine? An inside look.

Regenerative Patch Technologies advances its stem cell therapy for dry AMD, signaling a potential shift from merely slowing blindness to actively improving vision.

A strategic investment firm's move signals strong confidence in the closing of Avadel's multi-billion dollar deal, spotlighting its blockbuster sleep drug.

A new partnership is using AI to make 'living drugs' smarter and more effective, promising to revolutionize manufacturing and bring hope to patients.

A key advisory appointment reveals a pivotal trend in private equity: a move from deal-making to deep operational focus for maximizing portfolio returns.

Trinity Consultants' acquisition of CEQA/NEPA expert Meridian is more than a regional deal; it's a strategic move with deep implications for biopharma.

J.P. Morgan's 2026 outlook reveals how private markets, fueled by AI, are rebuilding the physical backbone of the global supply chain.

A new oral drug could eliminate the dangerous side effects of CAR T-Cell therapy, potentially making the breakthrough cancer treatment safer and more accessible.

Stunning trial data reveals an immunotherapy combo that slashes myeloma progression by 83%, offering not just longer life but a better quality of life.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

A.D.A.M. Innovations just launched ALUNAÉ, the world's first AI genomic-based skincare. Is this the future of beauty or a step too far?

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.

AskBio's gene therapies for Parkinson's and heart failure have received Japan's SAKIGAKE designation, promising a faster path to patients.

A new patent for its lead cancer drug in Japan is more than a legal win; it's a strategic move to secure a future market into the 2040s.